Proven innovation
Share innovation

COPDPredict: A digital self-monitoring solution with AI-enabled exacerbation prediction capability for people living with COPD

By Monica Spiteri, NEPESMO Limited Added 13th Oct, 2020 Updated 8th Dec, 2020

For COPD patients who experience frequent and severe exacerbations, COPDPredict™ is the only digital health solution that can predict an impending exacerbation at least seven days before onset, promptly and efficiently directing medical professionals and patients to adjust treatment and prevent hospitalisations. COPDPredict™ is superior to other remote tracking solutions as it is specifically designed to facilitate a model of care focussed on prevention by uniquely combining remote monitoring and patient-personalised exacerbation prediction. Patients benefit from AI-enabled preventative care closer to home and enhanced quality of life; payers benefit from resource cost savings.

About

COPDPredict is a CE-marked, OWASP-compliant, SaaS-based smart digital monitoring solution with AI-enabled exacerbation prediction capability. An app allows individuals with COPD to input, collect, log and track bio-clinical data on symptoms, lung function, biomarkers and treatment in their home. The app connects to Bluetooth-enabled smart hardware e.g. lung function monitors. Collected data is shared with and viewed in real-time by clinicians via a secure cloud-based clinical decision support platform. Smart analytics process data to generate patient-specific bio-clinical profiles; proprietary exacerbation prediction algorithms identify changes in COPD health status and stratify severity to provide clinicians with precise alerts of imminent exacerbations via email and SMS.  Patients receive notifications via their app. This permits timely appropriate intervention at home.

A six-month pilot on 90 patients demonstrated significant benefits with high sensitivity for exacerbation prediction, positive patient engagement, reduction in hospitalisations and cost savings.

COPDPredict can make a significant impact at two critical points:

 (a) In community care pathways for patients experiencing frequent exacerbations and/or severe episodes to prevent unnecessary hospitalisations.  

 (b) In hospital discharge bundles to save bed-days and prevent readmissions. 

Related Innovations